Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Factors affecting prognosis and mortality in severe COVID-19 pneumonia patients

Afşin et al., Acta Clinica Croatica, doi:10.20471/acc.2023.62.01.13
Aug 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 17% Improvement Relative Risk HCQ for COVID-19  Afşin et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 80 patients in Turkey (August - November 2020) Lower mortality with HCQ (not stat. sig., p=0.5) c19hcq.org Afşin et al., Acta Clinica Croatica, Aug 2023 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 80 hospitalized severe COVID-19 patients in Turkey, showing no significant difference with HCQ treatment in unadjusted results. All patients received favipiravir.
Although the 17% lower mortality is not statistically significant, it is consistent with the significant 26% lower mortality [22‑30%] from meta analysis of the 250 mortality results to date.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 16.7% lower, RR 0.83, p = 0.50, treatment 15 of 36 (41.7%), control 22 of 44 (50.0%), NNT 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Afşin et al., 1 Aug 2023, retrospective, Turkey, peer-reviewed, 2 authors, study period August 2020 - November 2020.
This PaperHCQAll
FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS
Emine Afşin, Muhammed Emin Demirkol, Prof Assoc Emine Afşin, MD Abant Izzet
doi:10.20471/acc.2023.62.01.13
Fatality rate in coronavirus disease 2019 (COVID-19) cases has been reported to be 3.4% worldwide. The aim of this study was to evaluate the factors that determine prognosis and mortality in severe COVID-19 pneumonia patients. Eighty adult patients with severe COVID-19 pneumonia hospitalized and monitored at Izzet Baysal State Hospital (Bolu, Turkey) between August and November 2020 were included in this retrospective single-center study. Demographic and laboratory data, severity of radiological involvement, comorbidities, agents used in treatment, and clinical results were recorded, and data were grouped as survivors and non-survivors. The mean patient age was 67.8±12.6 years. There were 59 (73.8%) male patients. Comorbid diseases were present in 53 (66.3%) patients. There was no significant relationship between patient age, gender, smoking status or presence of comorbidity and mortality (p>0.05). The variables such as pulmonary involvement above 50%, intubation, or ferritin (>434.8 µg/L), troponin I (>14.05 ng/L) and procalcitonin (>0.125 ng/mL) as the sole variables of laboratory data were found to have significant relationship with increased mortality (p<0.05). Mortality was significantly higher in patients using steroid pulse therapy + tocilizumab, steroid pulse therapy + hydroxychloroquine, or solely steroid pulse therapy, while it was significantly lower in patients receiving azithromycin therapy and those in the plasma + steroid pulse therapy group. The severity of pulmonary involvement, intubation, and increase in inflammation markers such as ferritin, troponin and procalcitonin were found to be significantly associated with mortality (p<0.05). Treatment approaches with azithromycin and plasma + steroid pulse therapy were found to reduce mortality.
References
Aktas, A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS-Cov-2 infection, Exp Biomed Res, doi:10.30714/j-ebr.2020463629
Andrianopoulos, Papathanasiou, Papathanakos, Chaidos, Koulouras, Tocilizumab's efficacy in patients with coronavirus disease 2019 (COVID-19) is determined by the presence of cytokine storm, J Med Virol, doi:10.1002/jmv.26209
Fernandez-Cruz, Ruiz-Antoran, Munoz-Gomez, López, Mills-Sánchez et al., A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother, doi:10.1128/AAC.01168-20
Furuta, Takahashi, Fukuda, Kuno, Kamiyama et al., In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother, doi:10.1128/AAC.46.4.977-981.2002
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/dst.2020.01047
Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein, Impact of sex and gender on COVID-19 outcomes in Europe, Biol Sex Differ, doi:10.1186/s13293-020-00304-9
Guaraldi, Meschiari, Cozzi-Lepri, Milic, Tonelli et al., Tocilizumab in patients with severe COVID-10: a retrospective cohort study. Lancet Rheumatol, doi:10.1016/S2665-9913
Guo, Fan, Chen, Wu, Zhang et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19), JAMA Cardiol, doi:10.1001/jamacardio.2020.1017
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with COVID-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2021436
Hu, Sun, Dai, Deng, Li et al., Prevalence and severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, J Clin Virol, doi:10.1016/j.jcv.2020.1043719
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736
Hung, To, Lee, Lee, Yan et al., Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection, Chest, doi:10.1378/chest.12-2907
Lan, Lai, Huang, Chang, Lu et al., Tocilizumab for severe COVID-19: a systematic review and meta-analysis, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106103
Lippi, Henry, Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19), Eur J Intern Med, doi:10.1016/j.ejim.2020.03.014
Lu, Chen, Chang, Potential therapeutic agents against COVID-19: what we know so far, J Chin Med Assoc, doi:10.1097/JCMA.0000000000000318
Mareev, Orlova, Pavlikova, Matskeplishvili, Krasnova et al., Steroid pulse-therapy in patients with COVID-19, systemic inflammation and risk of venous thrombosis and thromboembolism (WAYFARER Study), Kardiologiia, doi:10.18087/car-dio.2020.6.n1226
Monreal, De La Maza, Natera-Villalba, Beltrán-Corbellini, Rodríguez-Jorge et al., High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study, Eur J Clin Microbiol Infect Dis, doi:10.1007/s10096-020-04078-1
Petrak, Skorodin, Van Hise, Fliegelman, Pinsky et al., Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2, Clin Transl Sci, doi:10.1111/cts.12894
Rubio-Rivas, Padulles, Mitjavila, Riera-Mestre, García-Forero, Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.09.1486
Sažetak, Uzrokovanom, None
Sherren, Ostermann, Agarwal, Meadows, Ioannou et al., COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review, Br J Anaesth, doi:10.1016/j.bja.2020.08.050
Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med, doi:10.1056/NEJMoa2031304
Sit, Aktas, Ozer, Kocak, Erkus et al., Mean platelet volume: an overlooked herald of malignant thyroid nodules, Acta Clin Croat, doi:10.20471/acc.2019.58.03.03
Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of tocilizumab in patients hospitalized with COVID-19, N Engl J Med, doi:10.1056/NEJMoa2028836
Wadman, Couzin-Frankel, Kaiser, Matacic, How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes, Science
Wiersinga, Rhodes, Cheng, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19), JAMA, doi:10.1001/jama.2020.12839
Xia, Li, Wu, Wang, Zhu et al., Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion, Blood, doi:10.1182/blood.2020007079
Xie, Covassin, Fan, Singh, Gao et al., Association between hypoxemia and mortality in patients with COVID-19, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.04.006
{ 'indexed': {'date-parts': [[2023, 9, 13]], 'date-time': '2023-09-13T00:43:23Z', 'timestamp': 1694565803315}, 'reference-count': 0, 'publisher': 'Sestre Milosrdnice University Hospital Center (KBC Sestre milosrdnice)', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023]]}, 'DOI': '10.20471/acc.2023.62.01.13', 'type': 'journal-article', 'created': {'date-parts': [[2023, 9, 11]], 'date-time': '2023-09-11T09:41:05Z', 'timestamp': 1694425265000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Factors Affecting Prognosis and Mortality in Severe COVID-19 Pneumonia Patients', 'prefix': '10.20471', 'author': [{'given': 'Emine', 'family': 'Afşin', 'sequence': 'first', 'affiliation': []}], 'member': '8565', 'container-title': 'Acta Clinica Croatica', 'original-title': [], 'link': [ { 'URL': 'https://hrcak.srce.hr/file/443392', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 11]], 'date-time': '2023-09-11T09:41:24Z', 'timestamp': 1694425284000}, 'score': 1, 'resource': {'primary': {'URL': 'https://hrcak.srce.hr/clanak/443392'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.20471/acc.2023.62.01.13', 'relation': {}, 'ISSN': ['0353-9466'], 'subject': ['General Medicine'], 'container-title-short': 'ACC', 'published': {'date-parts': [[2023]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit